Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 14/20 | 0.51 |
| ▸ | GRIN1 | Q05586 | 14/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 14/20 | 0.51 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.49 |
| ▸ | TYMS | P04818 | 1/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16982959 | 0.85 | NOTUM (0.54) | RXRAGRIN1GRIN2BNOTUM | |
| SCHEMBL16991671 | 0.81 | AMY1A (0.49) | RXRAGRIN1GRIN2BAMY1ATYMS | |
| SCHEMBL17666284 | 0.78 | LRRK2 (0.50) | RXRAGRIN1GRIN2BAMY1ATYMS | |
| SCHEMBL17666319 | 0.77 | RXRA (0.47) | RXRAGRIN1GRIN2B | |
| SCHEMBL18456211 | 0.76 | BCHE (0.44) | RXRAGRIN1GRIN2BAMY1ATYMS | |
| SCHEMBL17666321 | 0.76 | RXRA (0.42) | RXRAGRIN1GRIN2BAMY1ATYMS | |
| SCHEMBL17666313 | 0.75 | RXRA (0.40) | RXRAGRIN1GRIN2BAMY1ATYMS | |
| SCHEMBL19211476 | 0.73 | RXRA (0.63) | RXRAGRIN1GRIN2BNOTUM | |
| SCHEMBL18456212 | 0.72 | NOTUM (0.41) | RXRAGRIN1GRIN2BAMY1ATYMS | |
| SCHEMBL16983098 | 0.72 | RXRA (0.47) | RXRAGRIN1GRIN2BNOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9453018-B2 | Pyrimidinones as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-09-27 | — | — | US | disclosed |
| US-20160096839-A1 | PYRIMIDINONES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160096839-A1 | PYRIMIDINONES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F2 | RXRA 4646/4885GRIN1 2872/4885GRIN2B 2964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.